Drugs / PID23
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07696481 | Aug 2026 → May 2029 expected | acute lymphoblastic leukemia, acute myeloid leukemia | Zhujiang Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PID23 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07696481 ↗ |
| Known as | PID23 Injection | “PID23 Injection is an innovative in vivo CAR-T therapy that delivers a viral vector encoding three targets (CD19, BCMA, and CD70) directly into patients” NCT07696481 ↗ |
| Action | Deplete | “enabling their own T cells to generate functional CAR-T cells against leukemia cells” NCT07696481 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT07696481 ↗ |
| Target | CD19 | “PID23 is an in vivo CAR-T product, a lentiviral vector encoding CD19, BCMA, and CD70 chimeric antigen receptors, administered as a single intravenous infusion” NCT07696481 ↗ |
| Target | CD70 | “PID23 is an in vivo CAR-T product, a lentiviral vector encoding CD19, BCMA, and CD70 chimeric antigen receptors, administered as a single intravenous infusion” NCT07696481 ↗ |